A1. Mickleborough TD, Vaughn CL, et al. Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respir Med. 2013 Aug;107(8):1152-1163.
B. Attention Deficit Hyperactivity Disorder
B1. Kean JD, Sarris J, et al. Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2017 Feb;234(3):403-420.
C1. Zawadzki M, Janosch C, et al. Perna canaliculus lipid complex PCSO-524™ demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control. Mar Drugs. 2013 Jun 5;11(6):1920-1935.
C2. Stebbings S, Gray A, et al. A randomized double-blind placebo-controlled trial to investigate the effectiveness and safety of a novel green-lipped mussel extract -BioLex® -for managing pain in moderate to severe osteoarthritis of the hip and knee. BMC Complement Altern Med. 2017 Aug 22;17(1):416.
C3. Liu X, Machado GC, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175.
D1. Sukumaran S, Pittman KB, et al. A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer. Ann Oncol. 2010 May;21(5):1089-1093.
D2. Coupe A, Howe L, et al. First report of Toxoplasma gondii sporulated oocysts and Giardia duodenalis in commercial green-lipped mussels (Perna canaliculus) in New Zealand. Parasitol Res. 2018 May;117(5):1453-1463.